PTPI (Petros Pharmaceuticals, Inc.) Forward P/S Multiple

Corporate emblem and logo of Petros Pharmaceuticals, Inc. (PTPI)

The forward P/S valuation for Petros Pharmaceuticals (PTPI), with GURU.Markets data illustrated on this chart, confirms the impact of men's health patents and strict FDA oversight. Meanwhile, the 0.20 level serves as a critical benchmark. Business efficiency is based on outsourcing production via CMOs to reduce costs, while revenue scaling relies on the development of direct-to-consumer digital sales.

PTPI (Petros Pharmaceuticals, Inc.) Price to Expected Revenue Ratio history from 07/04/2022 to 06/28/2025

PTPI (petrospharma.com): analytical breakdowns and indicator data

Comprehensive company analysis:Petros (PTPI)
Original product of Petros Pharmaceuticals

For the biopharmaceutical company Petros Pharmaceuticals (PTPI), whose operations are strictly regulated by FDA standards, the key value driver is the expected commercialization of its products. The forward P/S ratio compares current market capitalization with projected annual revenue, allowing investors to filter out emotional noise and determine the fair value of assets, utilizing this chart to identify entry points when the business potential is undervalued.

Key competitors

Forward P/S Multiple HLN (Haleon PLC)|Forward P/S Multiple Kenvue Corp KVUE|Verona Pharma PLC - Forward P/S Multiple|Market Cap to Future Revenue Ratio jyongbio.com|LGND: Forward P/S Multiple|Market Cap to Projected Revenue AMRX|Price-to-Projected Revenue Ratio Perrigo Company|Market Cap to Future Revenue Ratio Alvotech ALVO|Forward P/S Multiple LQDA|GLPG: Future Price to Revenue|Forward P/S Multiple ANIP (ANI Pharmaceuticals, Inc.)|Market Cap to Expected Sales Ratio MannKind Corp (MNKD)|AMPH: Forward Price-to-Revenue Multiple|Forward Price to Sales PCRX (Pacira)|ARS Pharmaceuticals (SPRY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TBPH|AQST (Aquestive Corp) - Forward P/S Multiple|Forward Price-to-Revenue Multiple scPharmaceuticals Inc. (SCPH)|Forward Price-to-Revenue Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharmaceuticals Holding) - Forward Price to Sales|Price-to-Projected Revenue Ratio SXT Pharmaceuticals SXTC|Forward Price to Sales EPRX|BHST - Price-to-Projected Revenue Ratio|eXoZymes (EXOZ) - Forward Price-to-Revenue Multiple|ORMP: Forward P/S Multiple|ENTX: Price to Expected Revenue Ratio|HYFT (ipatherapeutics.com) - Forward P/S Multiple|Forward P/S Multiple ABVC BioPharma|Price-to-Projected Revenue Ratio Cumberland Pharmaceuticals Inc. (CPIX)|QNTM (Quantum BioPharma Ltd.) - Forward Price to Sales|Forward P/S Multiple FGEN (fibrogen.com)|Telomir Pharmaceuticals (TELO) - Market Cap to Future Revenue Ratio|RANI - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Synergy CHC SNYR|RLYB: Forward P/S Multiple|Market Cap to Future Revenue Ratio Lexaria (LEXX)|Price-to-Projected Revenue Ratio Pulmatrix|Market Cap to Projected Revenue PTHL (ftzy.com.cn)|Forward P/S Multiple APM|Lyra Therapeutics, Inc. - Market Cap to Projected Revenue|Forward P/S Multiple IBO (impactbiomedinc.com)|TNFA: Market Cap to Projected Revenue|YCBD - Price-to-Projected Revenue Ratio|PRFX - Forward P/S Multiple|CYTO (altamiratherapeutics.com) - Forward Price-to-Revenue Multiple|LIPO - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple OPTN|Pieris Pharmaceuticals Inc (PIRS) - Market Cap to Expected Sales Ratio|Forward P/S Multiple PROC|Forward P/S Multiple Qilian International Corp (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP